Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter S. DiStefano
AddedMar 31, 2024
UpdatedMay 1, 2026
Peter S. DiStefano

Peter S. DiStefano

Board Member, Acylin Therapeutics

Peter S. DiStefano's Career

Acylin Therapeutics
Acylin Therapeutics

Seattle, WA, US

Board Member· Board
Zebra Biologics
Zebra Biologics

Concord, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter S. DiStefano's Career

Acylin Therapeutics
Acylin Therapeutics
Series A$6.4M92009Seattle, WA, US
Board Member· Board

Similar to Acylin Therapeutics

Regenacy PharmaceuticalsRegenacy PharmaceuticalsWaltham, MA, USTherapeuticsest. 2016Regenacy PharmaceuticalsWaltham, MA, US · est. 2016

Regenacy Pharmaceuticals: A clinical-stage biopharma firm innovating protein acetylation for chronic conditions.

Public · $17.1M8
Accent TherapeuticsAccent TherapeuticsLexington, MA, USDrug Developmentest. 2017Accent TherapeuticsLexington, MA, US · est. 2017

Accent Therapeutics, a NY-based biopharmaceutical company, specializes in developing inhibitory molecule drugs.

Series C · $178M69
Alcyone LifesciencesAlcyone LifesciencesLowell, MA, USMedical Devicesest. 2010Alcyone LifesciencesLowell, MA, US · est. 2010

Alcyone Lifesciences: Precision CNS therapy through optimized molecular brain technology.

Series B · $38.6M38
Alcinous PharmaceuticalsAlcinous PharmaceuticalsRumford, RI, USDrug Discoveryest. 2016Alcinous PharmaceuticalsRumford, RI, US · est. 2016

Alcinous Pharmaceuticals: Innovating in drug discovery for oncology and other diseases.

Seed · $600k2
Zebra Biologics
Zebra Biologics
Seed$12M82013Concord, MA, US
Co-Founder

Leadership at Zebra Biologics

Ronald LindsayRonald LindsayBoard Member
Phil FrostPhil FrostCo-Founder
Paul GreengardPaul GreengardCo-Founder
Richard LernerRichard LernerCo-Founder

Similar to Zebra Biologics

AltruBioAltruBioLos Altos, CA, USAntibody Therapeuticsest. 2000AltruBioLos Altos, CA, US · est. 2000

AltruBio, a global biotech firm, develops targeted antibody therapeutics for cancer and immune diseases.

Series A · $102.6M5
ZyngeniaZyngeniaGaithersburg, MD, USAntibody Drugsest. 2008ZyngeniaGaithersburg, MD, US · est. 2008

Zyngenia: A biotherapeutics company pioneering the development of next-gen antibody-derived drugs.

Public · $25M30
Amberstone BiosciencesAmberstone BiosciencesLaguna Hills, CA, USTherapeutic Antibodiesest. 2018Amberstone BiosciencesLaguna Hills, CA, US · est. 2018

Amberstone Biosciences innovatively develops therapeutic antibodies for unmet medical needs.

Series A · $13.3M19
Dren BioDren BioFoster City, CA, USTherapeutic Antibodiesest. 2019Dren BioFoster City, CA, US · est. 2019

Dren Bio: A biotech firm in San Carlos, CA, innovating protein-based solutions for disease treatment.

Series B · $130.1M63

People Similar to Peter S. DiStefano

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailGabriel SanchezGabriel SanchezCo-Founder & CEO · Zebra Medical TechnologiesRyan ProtzkoRyan ProtzkoCo-Founder · ZestBioPeter RobinsonPeter RobinsonCo-Founder · Enable BiosciencesBill BurnsBill BurnsBoard Member · Zebra TechnologiesFabio SofiaFabio SofiaCo-Founder · Symbiotics